Island Pharma begins Screening Patients for its ISLA-101 Phase 2 Trial
Island Pharmaceuticals has announced that they have received IRB approval from the US Army to begin screening patients to enroll in their ISLA-101 Phase 2 clinical study for Dengue fever. This announcement comes after the FDA requested that Island waits until the end of mosquito season to expose patients, to prevent unwanted transmission of the virus.
Island Pharma begins Screening Patients for its ISLA-101 Phase 2 Trial